{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:50:45Z","timestamp":1761519045859},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T00:00:00Z","timestamp":1341964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s10549-012-2157-7","type":"journal-article","created":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T13:15:09Z","timestamp":1341926109000},"page":"347-354","source":"Crossref","is-referenced-by-count":30,"title":["Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis"],"prefix":"10.1007","volume":"135","author":[{"given":"Aaron M.","family":"Drucker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau T.","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,11]]},"reference":[{"key":"2157_CR1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","volume":"5","author":"MC Franklin","year":"2004","unstructured":"Franklin MC, Carey KD, Vajdos FF et al (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317\u2013328","journal-title":"Cancer Cell"},{"key":"2157_CR2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cortes J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119","journal-title":"N Engl J Med"},{"key":"2157_CR3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","volume":"114","author":"ME Lacouture","year":"2009","unstructured":"Lacouture ME, Laabs SM, Koehler M et al (2009) Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 114:485\u2013493","journal-title":"Breast Cancer Res Treat"},{"key":"2157_CR4","first-page":"211","volume":"7","author":"Y Jia","year":"2009","unstructured":"Jia Y, Lacouture ME, Su X et al (2009) Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol 7:211\u2013217","journal-title":"J Support Oncol"},{"key":"2157_CR5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000229752","volume":"77","author":"X Su","year":"2009","unstructured":"Su X, Lacouture ME, Jia Y et al (2009) Risk of high-grade skin rash in cancer patients treated with cetuximab\u2014an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 77:124\u2013133","journal-title":"Oncology"},{"key":"2157_CR6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","volume":"13","author":"M Untch","year":"2012","unstructured":"Untch M, Loibl S, Bischoff J et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13:135\u2013144","journal-title":"Lancet Oncol"},{"key":"2157_CR7","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2005.05.4221","volume":"24","author":"MS Gordon","year":"2006","unstructured":"Gordon MS, Matei D, Aghajanian C et al (2006) Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324\u20134332","journal-title":"J Clin Oncol"},{"key":"2157_CR8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.2006.07.0888","volume":"25","author":"JS Bono de","year":"2007","unstructured":"de Bono JS, Bellmunt J, Attard G et al (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25:257\u2013262","journal-title":"J Clin Oncol"},{"key":"2157_CR9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2006.07.0649","volume":"25","author":"DB Agus","year":"2007","unstructured":"Agus DB, Sweeney CJ, Morris MJ et al (2007) Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25:675\u2013681","journal-title":"J Clin Oncol"},{"key":"2157_CR10","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2009.22.3354","volume":"28","author":"S Makhija","year":"2010","unstructured":"Makhija S, Amler LC, Glenn D et al (2010) Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215\u20131223","journal-title":"J Clin Oncol"},{"key":"2157_CR11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","volume":"28","author":"J Baselga","year":"2010","unstructured":"Baselga J, Gelmon KA, Verma S et al (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28:1138\u20131144","journal-title":"J Clin Oncol"},{"key":"2157_CR12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2009.24.1661","volume":"28","author":"L Gianni","year":"2010","unstructured":"Gianni L, Llado A, Bianchi G et al (2010) Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:1131\u20131137","journal-title":"J Clin Oncol"},{"key":"2157_CR13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25\u201332","journal-title":"Lancet Oncol"},{"key":"2157_CR14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803\u2013812","journal-title":"Nat Rev Cancer"},{"key":"2157_CR15","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/archdermatol.2011.719","volume":"147","author":"JH Borovicka","year":"2011","unstructured":"Borovicka JH, Calahan C, Gandhi M et al (2011) Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 147:1403\u20131409","journal-title":"Arch Dermatol"},{"key":"2157_CR16","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-10-0421","volume":"16","author":"B Nardone","year":"2010","unstructured":"Nardone B, Nicholson K, Newman M et al (2010) Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1\/2 inhibitors in cancer patients. Clin Cancer Res 16:4452\u20134460","journal-title":"Clin Cancer Res"},{"key":"2157_CR17","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.2005.03.184","volume":"23","author":"DB Agus","year":"2005","unstructured":"Agus DB, Gordon MS, Taylor C et al (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534\u20132543","journal-title":"J Clin Oncol"},{"key":"2157_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/sj.bjc.6602875","volume":"94","author":"I Laux","year":"2006","unstructured":"Laux I, Jain A, Singh S et al (2006) Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br J Cancer 94:85\u201392","journal-title":"Br J Cancer"},{"key":"2157_CR19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1535-6108(02)00097-1","volume":"2","author":"DB Agus","year":"2002","unstructured":"Agus DB, Akita RW, Fox WD et al (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127\u2013137","journal-title":"Cancer Cell"},{"key":"2157_CR20","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1038\/onc.2008.13","volume":"27","author":"Z Cai","year":"2008","unstructured":"Cai Z, Zhang G, Zhou Z et al (2008) Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2\/neu and the EGFR-p185her2\/neu complexes. Oncogene 27:3870\u20133874","journal-title":"Oncogene"},{"key":"2157_CR21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/j.1460-2075.1996.tb00356.x","volume":"15","author":"D Karunagaran","year":"1996","unstructured":"Karunagaran D, Tzahar E, Beerli RR et al (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254\u2013264","journal-title":"EMBO J"},{"key":"2157_CR22","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","volume":"16","author":"D Graus-Porta","year":"1997","unstructured":"Graus-Porta D, Beerli RR, Daly JM et al (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647\u20131655","journal-title":"EMBO J"},{"key":"2157_CR23","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1074\/jbc.271.11.6071","volume":"271","author":"RR Beerli","year":"1996","unstructured":"Beerli RR, Hynes NE (1996) Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 271:6071\u20136076","journal-title":"J Biol Chem"},{"key":"2157_CR24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00403-008-0853-2","volume":"300","author":"S Forsberg","year":"2008","unstructured":"Forsberg S, Ostman A, Rollman O (2008) Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase. Arch Dermatol Res 300:505\u2013516","journal-title":"Arch Dermatol Res"},{"key":"2157_CR25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1006\/excr.2001.5390","volume":"271","author":"IY Potter De","year":"2001","unstructured":"De Potter IY, Poumay Y, Squillace KA et al (2001) Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res 271:315\u2013328","journal-title":"Exp Cell Res"},{"key":"2157_CR26","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079\u20131095","journal-title":"Support Care Cancer"},{"key":"2157_CR27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351\u20131357","journal-title":"J Clin Oncol"},{"key":"2157_CR28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0781.2007.00273.x","volume":"23","author":"M Luu","year":"2007","unstructured":"Luu M, Lai SE, Patel J et al (2007) Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 23:42\u201345","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2157_CR29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2230.2011.04117.x","volume":"36","author":"M Luu","year":"2011","unstructured":"Luu M, Boone SL, Patel J et al (2011) Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clin Exp Dermatol 36:733\u2013738","journal-title":"Clin Exp Dermatol"},{"key":"2157_CR30","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390\u20135396","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2157_CR31","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","volume":"7","author":"B Burtness","year":"2009","unstructured":"Burtness B, Anadkat M, Basti S et al (2009) NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Cancer Netw 7(Suppl 1):S5\u2013S21 quiz S22-4","journal-title":"J Natl Compr Cancer Netw"},{"key":"2157_CR32","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","volume":"18","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Segaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509\u2013522","journal-title":"Support Care Cancer"},{"key":"2157_CR33","doi-asserted-by":"crossref","unstructured":"Chen AP, Setser A, Anadkat MJ et al (2012) Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. doi: 10.1016\/j.jaad.2012.02.010","DOI":"10.1016\/j.jaad.2012.02.010"},{"key":"2157_CR34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djm324","volume":"100","author":"M Edgerly","year":"2008","unstructured":"Edgerly M, Fojo T (2008) Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 100:240\u2013242","journal-title":"J Natl Cancer Inst"},{"key":"2157_CR35","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","volume":"116","author":"SS Joshi","year":"2010","unstructured":"Joshi SS, Ortiz S, Witherspoon JN et al (2010) Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116:3916\u20133923","journal-title":"Cancer"},{"key":"2157_CR36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"SL Boone","year":"2007","unstructured":"Boone SL, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152\u2013159","journal-title":"Oncology"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2157-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2157-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2157-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:34:04Z","timestamp":1559234044000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2157-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,11]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["2157"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2157-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,11]]}}}